Optimizing Hearing Outcomes in Nasopharyngeal Cancer Survivors in the Era of Modern Radiotherapy and Systemic Therapy
Cancers · 23.09.2024 · 16 (18) · 3237
DOI: 10.3390/cancers16183237 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 23.09.2024. Verfasst von Jason C S Ho und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hong Kong Research Grant Council General Research.
Abstract (Originalsprache)
Intensity-modulated radiation therapy (IMRT) improves disease control and reduces treatment-related toxicity in patients with localized nasopharyngeal carcinoma (NPC). However, due to the proximity of the auditory apparatus to the treatment volume and the frequent incorporation of cisplatin-based chemotherapy, treatment-related sensorineural hearing loss (SNHL) remains a common debilitating complication among NPC survivors. The reported crude incidence of SNHL following IMRT for NPC varies widely at 1–46% due to differences in auditory assessment methods and thresholds, follow-up durations, chemotherapy usage, and patient compositions. International guidelines and radiation dosimetric studies have recommended constraining the cochlear mean dose to less than 44–50 Gy, but the risk of SNHL remains high despite adherence to these constraints. Potential strategies to improve hearing outcomes in NPC survivors include cautious de-escalation of radiotherapy dose and volume, individualization of cochlear constraints, optimization of radiotherapy planning techniques, and the use of substitutes or alternative schedules for cisplatin-based chemotherapy. The addition of immune checkpoint inhibitors to chemoradiotherapy did not impact ototoxicity. Prospective studies that employ both objective and patient-reported auditory outcomes are warranted to test the long-term benefits of various approaches. This article aims to provide a comprehensive review of the incidence and radiation dose–toxicity relationship of SNHL in NPC survivors and to summarize potential strategies to optimize hearing outcomes in relation to nuances in radiotherapy planning and the selection of systemic therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China.
- Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong SAR, China.
ORCID-Profile: Jason C S Ho, Brigette B Y Ma
Förderung
- Hong Kong Research Grant Council General Research
Zitieren
APA
Ho, J. C. S., Ma, B. B. Y., & Chow, J. C. H. (2024). Optimizing Hearing Outcomes in Nasopharyngeal Cancer Survivors in the Era of Modern Radiotherapy and Systemic Therapy. Cancers, 16(18), 3237. https://doi.org/10.3390/cancers16183237
Vancouver
Ho JCS, Ma BBY, Chow JCH. Optimizing Hearing Outcomes in Nasopharyngeal Cancer Survivors in the Era of Modern Radiotherapy and Systemic Therapy. Cancers. 2024;16(18):3237. doi:10.3390/cancers16183237
BibTeX
@article{Ho2024,
author = {Ho, Jason C S and Ma, Brigette B Y and Chow, James C H},
title = {Optimizing Hearing Outcomes in Nasopharyngeal Cancer Survivors in the Era of Modern Radiotherapy and Systemic Therapy},
journal = {Cancers},
year = {2024},
volume = {16},
number = {18},
pages = {3237},
doi = {10.3390/cancers16183237}
}
EUVIMED